BusinessMersana Therapeutics Outlines 2017 Milestones and 2018 GoalsBy Nasdaq OMXJan 8, 2018, 1:02 PM UTC
BusinessMersana Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceBy Nasdaq OMXDec 20, 2017, 9:01 PM UTC
BusinessMersana Therapeutics Added to NASDAQ Biotechnology IndexBy Nasdaq OMXDec 15, 2017, 1:00 PM UTC
BusinessMersana Announces First Patient Dosed with XMT-1536 in Phase 1 Study in Patients with NaPi2b-Expressing TumorsBy Nasdaq OMXDec 12, 2017, 1:03 PM UTC
BusinessMersana Announces Third Quarter 2017 Financial Results and Provides Business UpdatesBy Nasdaq OMXNov 9, 2017, 9:01 PM UTC
BusinessMersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2bBy Nasdaq OMXOct 30, 2017, 11:30 AM UTC
BusinessMersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International ConferenceBy Nasdaq OMXOct 30, 2017, 11:00 AM UTC
BusinessMersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBy Nasdaq OMXOct 23, 2017, 8:01 PM UTC
